| |
Molecular Network Analysis and Phosphoproteomics
The goal of this initiative is to develop protein microarray technology for signal
pathway profiling and phosphoproteomic analysis in clinical specimens. We have
developed a new type of protein microarray, reverse phase arrays, which allow
dozens to hundreds of phosphorylation endpoints to be analyzed simultaneously
from as little as 10,000 cells.
For more information, you can download any of the attachments within the following
three general areas:
Our current standard operating procedures (SOPs) for the entire method.
A sampling of some of our recent publications highlighting the use of this new tool.
- Protein Array Primer- Cancer Cell, 2003
- Reverse Phase Array/ Prostate- Oncogene, 2001
- Clinical Proteomics- Nature Drug Discovery, 2002
- Ovarian Cancer Signaling- Proteomics, 2003
- Prostate Cancer Signaling- Proteomics, 2003
- Clinical Applications- Proteomics, 2003
- Mitochondrial Applications- Proteomics, 2003
- Proteomic Profiling of NCI60 Cell Lines- PNAS, 2003
- Regulatory Perspective of Microarray Technology, Nature Genetics, 2002
Our most recent spreadsheet of all western blot validated antibodies that
are commercially avaliable and can be used on the arrays. This validation is
part of a collaborative effort between our program and the laboratory of Dr.
Gordon Mills at the MD Anderson Cancer Center, acknowledging especially Yiling
Lu and Doris Siwak.
|
